This program will address the rapidly evolving field of shunt therapy as a treatment for heart failure. Specific populations of heart failure where this therapy may be most applicable will be discussed, along with the specific shunt types currently being tested. Results from studies already reported will be reviewed, combined with a look at the short and longer-term horizons for this therapeutic category.
CME ACCREDITATION AND DESIGNATION
The Cardiovascular Research Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Cardiovascular Research Foundation designates this activity for a maximum of 1.0 AMA PRA Category 1 Credits™ for physicians. Physicians can claim credit commensurate with the extent of their participation in the activity.
Participants will earn MOC points equivalent to the number of CME credits claimed for the activity. Successful completion of this CME activity enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.
It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting American Board of Internal Medicine (ABIM) MOC points.
ACTIVITY EVALUATION
Evaluation by questionnaire will address content, presentation effectiveness, possible bias, and future educational needs.
To obtain CME credit for this activity, participants must review all CME information, view all presentations in their entirety, and complete the Activity Evaluation Form. If you have any questions, please contact Thaifa Smith at tsmith@crf.org.
By the end of this program, participants should be able to:
• Understand the various types of heart failure, including proposed sub-categories of HFpEF phenotypes.
• Describe the physiological basis for shunt therapy, and the differences in the various approaches to establishing shunts.
• Appreciate the disparities in the current data sets and the challenges in trial design and data interpretation.
THT 2024 is designed for a multidisciplinary audience that includes anyone interested in heart failure management and a comprehensive overview of existing and investigational interventions. This includes:
• Heart failure specialists (fellows, nurses, physicians, physician assistants, and research coordinators)
• Cardiac imaging specialists
• Cardiac and vascular surgeons
• Clinical cardiologists
• Fellows in interventional cardiovascular medicine and related fields
• Industry professionals
• Interventional cardiologists
• Medical device experts
• Nurse practitioners
• Physician assistants
• Research scientists
In accordance with the appropriate accrediting bodies, all planners, teachers, and authors with control over activity content are required to disclose to the provider any financial relationships within the last 24 months with ineligible companies.
Accredited providers are required to provide this information to learners before the start of an activity. Discussion of off-label product usage during live cases is made at the sole discretion of the faculty. Off-label product discussion and usage are not endorsed by the Cardiovascular Research Foundation or the conference directors of this activity.
CME Reviewer(s) and Associate Course Directors(s):
Gary S. Mintz, MD — Consultant Fee/Honoraria/Speaker's Bureau - Boston Scientific Corporation; Abbott; SpectraWave; Gentuity.
Grzegorz L. Kaluza, MD, PhD — Grant Support/Research Contract - 4C Medical; Terumo Medical Corporation; Bristol-Myers Squibb; Edwards Lifesciences; Advanced Nano Technologies; Adriakaim; Reflow Medical; Tenaya Therapeutics; Shape Memory Medical; Occlutech; Neochord; MicroInterventional Devices; Lungpacer; Inozyme; InnovHeart; HLT; Deinde Medical; Ancora Heart; Cardiac Implants; Dura Biotech; Soundbite Medical Solutions; Mitria; InQB8; Ethicon; R3 Vascular; Puzzle Medical; ReCardia; StrideBio; VivaSure; Magenta Medical; Canon; Thubrikar Aortic Valve; Cardiovascular Systems, Inc.; Acotec Scientific; Microbot; Philips; Zoll; Cook Medical; Medtronic; ReValve Medical; Orchestra Biomed; Microtech; Motus GI; MicroVention; Takeda Pharmaceuticals; Hydrocision; Encompass Technologies; Retriever Medical; Siemens Healthineers; Trisol Medical; IntraTech; Abbott; Bayliss Medical; Dropshot Therapeutics; Abiomed; Autonomix; UltraVet; Meacor; AMX Medical; JensCare.
Donald E. Cutlip, MD — Nothing to disclose.
Thaifa Smith – Nothing to disclose.
Yullee Lai – Nothing to disclose.
CRF identifies relevant financial relationships and mitigates them before the activity begins. The CME associate course directors documented that all relevant financial relationships have been mitigated as of 2/6/2024.
The Cardiovascular Research Foundation ensures that its programs are educational and meet the needs of the target audience. This program was developed without the influence from commercial supporters.
This enduring webcast was supported by Edwards Lifesciences.